Biotech Mailbag: All About Alnylam

This column originally posted on RealMoney.com at 6:59 a.m. EST. For more information about subscribing to RealMoney, please click here.

Pass the stuffing and please, more cranberry sauce! The Thanksgiving Biotech Mailbag is open for business.

Robert C. writes:

"What is your opinion and record of following Alnylam Pharmaceuticals (ALNY Quote)? I am a physician with a research background and although I know that major pitfalls exist of function and approval I cannot see why there is not more interest in this potentially life-changing therapy."

Take your eyes off Alnylam's stock chart for a moment and glance at the company's balance sheet, which will be laden with more than $500 million when the year comes to a close. ...